DASON COVID-19 Weekly Treatment Literature Update 6/15/2020
Prepared by: Angelina Davis, PharmD, MS, April Dyer, PharmD, MBA, MSCR, Elizabeth Dodds Ashley, PharmD, MHS, Melissa Johnson, PharmD, MHS, S. Shaefer Spires, MD, Travis Jones, PharmD

The following summarizes key literature pertaining to treatment of COVID-19 during the past week.
*Note: some of the data discussed below is in pre-print form that has not yet been peer-reviewed. We have noted some discrepancies in some of this data, and final printed versions may ultimately differ from what is shown here. We will update as soon as possible; caution is advised when interpreting this literature.

**Remdesivir**
**Remdesivir Access:** Additional shipments continue to be distributed to state health departments. Data regarding shipments to states is now being posted to the Public Health Emergency website. This week, the site was updated to indicate state shipments beginning 6/15/2020.
https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Pages/remdesivir.aspx

*The remdesivir summary table with the information of published studies to date can be found at this link:* https://dason.medicine.duke.edu/summary-recent-clinical-data-use-remdesivir-covid-19

Beginning with data for July 2020, the CDC will now require submission of data on remdesivir use as part of antimicrobial use (AU) data submissions to NHSN. The DASON team is aware and is already receiving data feeds regarding remdesivir from many hospitals. We will be prepared to handle this submission as soon as NHSN updates are complete. For any hospitals where remdesivir data are not already in the routine data feeds, your DASON liaison will be reaching out with more information. We will work with your IT department to ensure the data are in the standard DASON eMAR before the July reporting deadlines.

**Hydroxychloroquine**
**Hydroxychloroquine Data:** *The summary table is available at this link:* https://dason.medicine.duke.edu/summary-recent-clinical-data-use-hydroxychloroquine-and-chloroquine-covid-19

On Monday 6/15/2020, the US FDA revoked the Emergency Use Authorization (EUA) for hydroxychloroquine and chloroquine after determining the drugs no longer meet legal criteria for issuing an EUA. This was specifically based on the FDA assessment that the drugs will likely not be effective in the setting of ongoing reports of toxicity. Read the full announcement here: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and.